Paul Bolno, Wave Life Sciences CEO
Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates
Wave Life Sciences has picked up another deal with a major pharma company.
The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance oligonucleotide therapeutics. This includes moving along Wave’s RNA editing program that targets alpha-1 antitrypsin deficiency, dubbed WVE-006, which affects both the lungs and liver with limited treatment options.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters